S.Amdt. 1300

SA 1300. Mr. BURR submitted an amendment intended to be proposed to
amendment SA 891 proposed by Mr. Schumer (for himself, Mr. Wyden, Mrs.
Murray, Mr. Brown, Mr. Peters, Mr. Cardin, Ms. Cantwell, Ms. Stabenow,
Mr. Tester, Mr. Menendez, Mr. Schatz, Mr. Carper, Mr. Leahy, and Mr.
Sanders) to the bill H.R. 1319, to provide for reconciliation pursuant
to title II of S. Con. Res. 5; which was ordered to lie on the table;
as follows:
Strike section 2501 and insert the following:

SEC. 2501. RESEARCH AND DEVELOPMENT OF MEDICAL
COUNTERMEASURES AND ANCILLARY MEDICAL SUPPLIES.

(a) In General.--In addition to amounts otherwise
available, there is appropriated to the Secretary of Health
and Human Services (in this subtitle referred to as the
``Secretary'') for fiscal year 2021, out of any money in the
Treasury not otherwise appropriated, $7,660,000,000, to
remain available through September 30, 2031, necessary
expenses with respect to the research, development,
manufacturing, production, and purchase, at the discretion of
the Secretary, of vaccines, therapeutics, ancillary supplies
necessary for the administration of such vaccines and
therapeutics, and medical devices to prevent, prepare for,
and respond to SARS-CoV-2, or any viral variant mutating
therefrom with pandemic potential and COVID-19, or other
public health threats, of which--
(1) $3,064,000,000 shall be for the Biomedical Advanced
Research and Development Authority to support the research,
advanced research, development, manufacturing, and
procurement of medical countermeasures, which may include
supporting, maintaining, and improving domestic manufacturing
surge capacity of medical products or platform technologies
for use during a public health emergency, pursuant to section
319L of the Public Health Service Act (42 U.S.C. 247d-7e);
(2) $1,149,000,000 shall be for the Strategic National
Stockpile pursuant to section 319F-2 of the Public Health
Service Act (42 U.S.C. 247d-6b) related to the procurement
and maintenance of medical products and ancillary medical
supplies necessary to respond to public health threats, which
may include through the establishment and maintenance of
domestic manufacturing surge capacity or vendor managed
supply reserves;
(3) $1,532,000,000 shall be for the National Institutes of
Health to support the research and development of medical
countermeasures, including broad-spectrum antivirals for
SARS-CoV-2;
(4) $766,000,000 shall be for the Biomedical Advanced
Research and Development Authority to support the research
and development of broad-spectrum antiviral drugs for SARS-
CoV-2; and
(5) $1,149,000,000 shall be for the Secretary for rapid
screening, identification, and development of compounds and
platform technologies that may support preparedness for and
response to a potential public health threat.
______